tilatamig samrotecan (AZD9592) - AstraZeneca
AZD9592: Data from P1 EGRET trial (NCT05647122) for advanced solid tumors/NSCLC/HNSCC/CRC in H2 2025 (AstraZeneca) - Apr 29, 2025 - Q1 2025 Results 
P1 data Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck
https://www.astrazeneca.com/content/astraz/investor-relations/q1-2025-results-event.html
 
Apr 29, 2025
 
 
512f83fd-3947-4080-81ad-5cba97f4ed4d.png